大葉大學圖書館 |

The adenosinergic system[electronic resource] :a non-dopaminergic target in Parkinson's disease /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	616.833061
書名/作者:	The adenosinergic system : a non-dopaminergic target in Parkinson's disease // edited by Micaela Morelli, Nicola Simola, Jadwiga Wardas.
其他作者:	Morelli, Micaela.
出版者:	Cham : : Springer International Publishing :, 2015.
面頁冊數:	xii, 337 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Parkinson’s disease.
標題:	Parkinson’s disease - Treatment.
標題:	Parkinson’s disease - Alternative treatment.
標題:	Biomedicine.
標題:	Neurosciences.
標題:	Neurology.
ISBN:	9783319202730
ISBN:	9783319202723
內容註:	Adenosine A2A receptors: localization and function -- Allosteric Mechanisms in the adenosine A2A-dopamine D2 receptor heteromer -- Adenosine A2A receptor antagonists in drug development -- Adenosine A2A Receptors and Neurotrophic Factors: Relevance for Parkinson's Disease -- Role of adenosine A2A receptors in the control of neuroinflammation - relevance for Parkinson's disease -- Purines in Parkinson's: Adenosine A2A receptors and urate as targets for neuroprotection -- Adenosine A2A receptor antagonists as drugs for symptomatic control of Parkinson's disease in preclinical studies -- Dopamine/adenosine interactions related to tremor in animal models of Parkinsonism -- Adenosine A2A receptor antagonists in L-DOPA-induced motor fluctuations -- Adenosine A2A receptor-mediated control of non-motor functions in Parkinson's disease -- Imaging Studies with A2A Receptor Antagonists -- Caffeine and neuroprotection in Parkinson's disease -- The story of istradefylline - the first approved A2A antagonist for the treatment of Parkinson's disease -- Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson's Disease -- Adenosinergic regulation of sleep-wake behavior in the basal ganglia.
摘要、提要註:	Adenosine A2A receptor antagonists have shown great promise in the treatment of Parkinson's Disease and alleviation of symptoms. This book addresses various aspects of this class of drugs from their chemical development to their clinical use. Among the many insightful chapters contained in this book, there are three unique reviews that have not previously been published in any format: (1) a history of istradefylline, the first A2A antagonist approved for treatment of Parkinson's Disease, (2) an overview of neuroimaging studies in human health and disease, and (3) a study of urate as a possible biomarker and neuroprotectant.
電子資源:	http://dx.doi.org/10.1007/978-3-319-20273-0

The adenosinergic system[electronic resource] :a non-dopaminergic target in Parkinson's disease /
The adenosinergic systema non-dopaminergic target in Parkinson's disease /[electronic resource] :edited by Micaela Morelli, Nicola Simola, Jadwiga Wardas. - Cham :Springer International Publishing :2015. - xii, 337 p. :ill., digital ;24 cm. - Current topics in neurotoxicity,v.102363-9563 ;. - Current topics in neurotoxicity ;1..

Adenosine A2A receptors: localization and function -- Allosteric Mechanisms in the adenosine A2A-dopamine D2 receptor heteromer -- Adenosine A2A receptor antagonists in drug development -- Adenosine A2A Receptors and Neurotrophic Factors: Relevance for Parkinson's Disease -- Role of adenosine A2A receptors in the control of neuroinflammation - relevance for Parkinson's disease -- Purines in Parkinson's: Adenosine A2A receptors and urate as targets for neuroprotection -- Adenosine A2A receptor antagonists as drugs for symptomatic control of Parkinson's disease in preclinical studies -- Dopamine/adenosine interactions related to tremor in animal models of Parkinsonism -- Adenosine A2A receptor antagonists in L-DOPA-induced motor fluctuations -- Adenosine A2A receptor-mediated control of non-motor functions in Parkinson's disease -- Imaging Studies with A2A Receptor Antagonists -- Caffeine and neuroprotection in Parkinson's disease -- The story of istradefylline - the first approved A2A antagonist for the treatment of Parkinson's disease -- Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson's Disease -- Adenosinergic regulation of sleep-wake behavior in the basal ganglia.

Adenosine A2A receptor antagonists have shown great promise in the treatment of Parkinson's Disease and alleviation of symptoms. This book addresses various aspects of this class of drugs from their chemical development to their clinical use. Among the many insightful chapters contained in this book, there are three unique reviews that have not previously been published in any format: (1) a history of istradefylline, the first A2A antagonist approved for treatment of Parkinson's Disease, (2) an overview of neuroimaging studies in human health and disease, and (3) a study of urate as a possible biomarker and neuroprotectant.

ISBN: 9783319202730

Standard No.: 10.1007/978-3-319-20273-0doiSubjects--Topical Terms:

634545
Parkinson’s disease.

LC Class. No.: RC382 / .A34 2015

Dewey Class. No.: 616.833061

The adenosinergic system[electronic resource] :a non-dopaminergic target in Parkinson's disease /
LDR:02915nam a2200325 a 4500 001 443668
003 DE-He213
005 20160406172342.0
006 m d
007 cr nn 008maaau
008 160715s2015 gw s 0 eng d
020 $a 9783319202730 $q (electronic bk.)
020 $a 9783319202723 $q (paper)
024 7 $a 10.1007/978-3-319-20273-0 $2 doi
035 $a 978-3-319-20273-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RC382 $b .A34 2015
072 7 $a PSAN $2 bicssc
072 7 $a MED057000 $2 bisacsh
082 0 4 $a 616.833061 $2 23
090 $a RC382 $b .A232 2015
245 0 4 $a The adenosinergic system $h [electronic resource] : $b a non-dopaminergic target in Parkinson's disease / $c edited by Micaela Morelli, Nicola Simola, Jadwiga Wardas.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a xii, 337 p. : $b ill., digital ; $c 24 cm.
490 1 $a Current topics in neurotoxicity, $x 2363-9563 ; $v v.10
505 0 $a Adenosine A2A receptors: localization and function -- Allosteric Mechanisms in the adenosine A2A-dopamine D2 receptor heteromer -- Adenosine A2A receptor antagonists in drug development -- Adenosine A2A Receptors and Neurotrophic Factors: Relevance for Parkinson's Disease -- Role of adenosine A2A receptors in the control of neuroinflammation - relevance for Parkinson's disease -- Purines in Parkinson's: Adenosine A2A receptors and urate as targets for neuroprotection -- Adenosine A2A receptor antagonists as drugs for symptomatic control of Parkinson's disease in preclinical studies -- Dopamine/adenosine interactions related to tremor in animal models of Parkinsonism -- Adenosine A2A receptor antagonists in L-DOPA-induced motor fluctuations -- Adenosine A2A receptor-mediated control of non-motor functions in Parkinson's disease -- Imaging Studies with A2A Receptor Antagonists -- Caffeine and neuroprotection in Parkinson's disease -- The story of istradefylline - the first approved A2A antagonist for the treatment of Parkinson's disease -- Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson's Disease -- Adenosinergic regulation of sleep-wake behavior in the basal ganglia.
520 $a Adenosine A2A receptor antagonists have shown great promise in the treatment of Parkinson's Disease and alleviation of symptoms. This book addresses various aspects of this class of drugs from their chemical development to their clinical use. Among the many insightful chapters contained in this book, there are three unique reviews that have not previously been published in any format: (1) a history of istradefylline, the first A2A antagonist approved for treatment of Parkinson's Disease, (2) an overview of neuroimaging studies in human health and disease, and (3) a study of urate as a possible biomarker and neuroprotectant.
650 0 $a Parkinson’s disease. $3 634545
650 0 $a Parkinson’s disease $x Treatment. $3 634546
650 0 $a Parkinson’s disease $x Alternative treatment. $3 634547
650 1 4 $a Biomedicine. $3 463454
650 2 4 $a Neurosciences. $3 372208
650 2 4 $a Neurology. $3 402687
700 1 $a Morelli, Micaela. $3 634542
700 1 $a Simola, Nicola. $3 634543
700 1 $a Wardas, Jadwiga. $3 634544
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
830 0 $a Current topics in neurotoxicity ; $v 1. $3 466086
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-20273-0
950 $a Biomedical and Life Sciences (Springer-11642)